Skip to main content
. 2023 Mar 22;14:1566. doi: 10.1038/s41467-023-36878-2

Fig. 9. The combination of radiotherapy, AZD7762 and PD-1/PD-L1 blockade improves the survival of glioma-bearing mice in GL261 glioma model.

Fig. 9

a The schematic representation of the dosing scheme followed for the survival experiment. b (Left) KM survival curves for GL261 glioma-bearing C57BL/6 mice. Survival analysis was performed using the log-rank test. The median survival duration in the treatment groups were as follows: Rad + VC + IgG, 33 days; Rad + VC + anti-PD-1, 34 days; Rad + AZD7762 + IgG, 29.5 days; Rad + AZD7762 + anti-PD-1, 38.5 days. Statistics: Rad + VC + IgG vs Rad + VC + anti-PD-1, p = 0.16; Rad + VC + IgG vs Rad + AZD7762 + IgG, p = 0.71; and Rad + VC + IgG vs Rad + AZD7762 + anti-PD-1, p = 0.008. (Right) KM survival curves for GL261 glioma-bearing C57BL/6 mice. Survival analysis was performed using the log-rank test. The median survival duration in the treatment groups were as follows: Rad + VC + IgG, 33 days; Rad + VC + anti-PD-L1, 40.5 days; Rad + AZD7762 + IgG, 29.5 days; Rad + AZD7762 + anti-PD-L1, undefined. Statistics: Rad + VC + IgG vs Rad + VC + anti-PD-L1, p = 0.059; Rad + VC + IgG vs Rad + AZD7762 + IgG, p = 0.71; and Rad + VC + IgG vs Rad + AZD7762 + anti-PD-L1, p = 0.0062. c KM survival curves for GL261 glioma-bearing CD8 KO mice. Survival analysis was performed using the log-rank test. The median survival duration in the treatment groups were as follows: Rad + VC + IgG, 23.5 days; Rad + VC + anti-PD-1, 23 days; Rad + AZD7762 + IgG, 24 days; Rad + AZD7762 + anti-PD-1, 24 days. Statistics: Rad + VC + IgG vs Rad + VC + anti-PD-1, p = 0.66; Rad + VC + IgG vs Rad + AZD7762 + IgG, p = 0.7; and Rad + VC + IgG vs Rad + AZD7762 + anti-PD-1, p = 0.78. Statistical significance on the figure is depicted as ns: not statistically significant, *p < 0.05, **p < 0.01. Source data for b, c are provided as a Source Data file.